Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06790875

Effects of Low Tidal Volume and Airway Pressure Release Ventilation on Lung Tissue Mechanics in ARDS Patients Under Mechanical Ventilation: A Prospective Randomized Crossover Study

The goal of this clinical trial is to learn how low tidal volume ventilation (LTV) and airway pressure release ventilation (APRV) affect lung tissue mechanics in adults with ARDS. The main questions it aims to answer are:

Does LTV or APRV improve lung tissue mechanics in patients with ARDS under mechanical ventilation? Researchers will compare LTV and APRV to see which ventilation mode works better for improving lung mechanics and patient safety.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Location status: Recruiting

Location contact

Xiaojing Zou Professor

CONTACT

[email protected]

13995518630

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meets the diagnostic criteria of the 2023 Global New Definition of ARDS.
  • Age: 18-80 years.
  • PaO2/FiO2 ≤ 200.
  • Within 12 hours of invasive mechanical ventilation treatment.
  • Obtain consent from the patient or their family members to participate in the study, and sign the informed consent form.

Exclusion criteria

  • Age < 18 years or > 80 years.
  • Uncorrected shock of any type.
  • Chronic obstructive pulmonary disease (COPD), pulmonary embolism, right heart failure, pulmonary hypertension, or severe arrhythmia.
  • Contraindications for using Electrical Impedance Tomography (EIT) (extensive chest skin damage, infection, pacemaker implantation, implanted automatic defibrillator, etc.), pneumothorax, mediastinal emphysema, or large pleural effusion.
  • Pregnant or breastfeeding women.
  • Patients planned for ECMO treatment.
  • Patients currently participating in or previously enrolled in other clinical studies.

Treatment and study plan

Airway Pressure Release Ventilation (APRV)

Device

In this arm, participants will receive airway pressure release ventilation (APRV), a form of pressure-controlled mechanical ventilation. The high pressure (Phigh) is set based on the plateau pressure of the LTV mode, with a low pressure (Plow) set at 0 cmH₂O. The high pressure time (Thigh) will be set to 4-6 seconds to maintain alveolar recruitment, while the low pressure time (Tlow) will be set to 0.2-0.6 seconds to optimize expiratory flow. This arm aims to evaluate the effects of APRV on lung tissue mechanics, oxygenation, and overall respiratory function in ARDS patients.

Primary outcomes

  1. Impact of low tidal volume vs airway pressure release ventilation on Dynamic relative regional lung strain(DRRS)

    Time frame: Maximum 4 hours

Secondary outcomes

  1. mechanical power(MP)

    Time frame: Maximum 4 hours

  2. platform pressure

    Time frame: Maximum 4 hours

  3. mean airway pressure

    Time frame: Maximum 4 hours

Study contacts

Contact information is provided by the study sponsor or research team.

Xiaojing Zou Professor

CONTACT

[email protected]

13995518630

Sponsors and collaborators

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 24, 2025
Registry last updated
Jan 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.